Trump’s Drug-Price Point Man Worked On CAR-T Demo While His Former Employer Sought To Buy Competing CAR-T Drug

July 11, 2018
Joe Grogan, the White House’s point man on drug-price policy, worked on a Medicare payment model for Novartis’ expensive cancer treatment while Gilead, his former employer, tried to buy a competing CAR-T treatment, according to Rep. Elijah Cummings (D-MD), who is investigating what he believes is a conflict of interest. White House Office of Management and Budget Associate Director of Health Programs Joe Grogan recused himself from work on the CAR-T demonstration when Gilead announced it acquired the maker of...

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on the coming Democrat-controlled House of Representatives, drug pricing reforms, Medicaid policy, FDA news and much more.